Delivery of vectors expressing short hairpin RNA for cancer therapy

DOI Web Site 26 References
  • Nishikawa Makiya
    Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Takahashi Yuki
    Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Takakura Yoshinobu
    Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University

Bibliographic Information

Other Title
  • 遺伝子・核酸医薬品のデリバリー　　がん治療のためのｓｈｏｒｔ　ｈａｉｒｐｉｎ　ＲＮＡ発現ベクターのデリバリー
  • がん治療のためのshort hairpin RNA発現べクターのデリバリー
  • ガン チリョウ ノ タメノ short hairpin RNA ハツゲン ベ クター ノ デリバリー

Search this article

Abstract

Cancer is linked to abbarent gene expression, so that its correction can be an effective approach to treating cancer patients. Silencing oncogenes or other genes contributing to tumor progression or metastasis will provide a cancer-specific therapy with minimal side effects.<BR>RNA interference has realized the silencing of target mRNA expression in a sequence-specific manner. Both small interfering RNA (siRNA) and vectors expressing short hairpin RNA (shRNA) have been reported to be effective in silencing the genes of interest once they enter target cells. Plasmid DNA expressing shRNA (pshRNA) inhibits the expression of target genes for a longer period of time than siRNA. Because gene expression can be silenced only in cells reached by pshRNA, its delivery to tumor cells is an important factor determining its efficacy on cancer therapy.<BR>Here we review several approaches to delivering pshRNA to tumor cells for cancer therapy.

Journal

  • Drug Delivery System

    Drug Delivery System 22 (2), 123-130, 2007

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(26)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top